Legend Biotech Corp
Legend Biotech Corp is a Healthcare company operating in Biotechnology with a $5.19B market cap.
Most recent earnings call: Q1 FY26 on May 12, 2026.
11 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks LEGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 9/10 quarters
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LEGN.
$ curl https://api.spokenalpha.com/v1/companies/LEGNFAQ
Spoken Alpha indexes LEGN's earnings call transcripts at https://spokenalpha.com/companies/LEGN. Each call links to attributed speakers and parsed analyst Q&A. Legend Biotech Corp's own investor relations page is at https://investors.legendbiotech.com/investor-relations.
Legend Biotech Corp (LEGN) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
Legend Biotech Corp (LEGN) operates in the Healthcare sector (Biotechnology industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.27 | $3.40 | -3.7% | +1.8% | +4.1% |
| Q4 FY2026 | $3.22 | $3.20 | +0.7% | -5.6% | -4.7% |
| Q3 FY2026 | $3.24 | $3.44 | -5.7% | -6.7% | -8.1% |
| Q2 FY2026 | $3.05 | $3.31 | -8.0% | -2.9% | -2.9% |
| Q1 FY2025 | $3.14 | $3.28 | -4.3% | -8.0% | -9.7% |
| Q4 FY2025 |
| $3.05 |
| $3.38 |
| -9.9% |
| -0.6% |
| -0.7% |
| Q3 FY2025 | $3.29 | $3.38 | -2.7% | +2.4% | +4.6% |
| Q2 FY2025 | $3.23 | $3.37 | -4.1% | -3.5% | -3.6% |
| Q1 FY2024 | $3.17 | $3.31 | -4.2% | -1.9% | -1.3% |
| Q4 FY2024 | $3.18 | $3.32 | -4.2% | -7.7% | -9.3% |